Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06110507
  4. Details
NCT06110507 Clinical Trial

Chronic Anergic-anhedonic Depression Open Trial

Depressive Disorder, Treatment-Resistant Clinical Trial

— CADOT  

Official title:
Chronic Anergic-anhedonic Depression Open Trial

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06110507
Other study ID # 8903
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 1, 2023
Est. completion date March 22, 2024

Study information
Verified date October 2023
Source University Hospital, Strasbourg, France
Contact Jack FOUCHER, MD, PhD
Phone 33 3 88 11 69 21
Email jack.foucher@chru-strasbourg.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A form of depression called 'dopamine-sensitive anergic-anhedonic syndrome is usually resistant to standard therapies (TRAD). On the other hand, they respond to dopaminergic approaches for which recommendations have been developed: DATA ('Dopaminergic Antidepressant Therapy Algorithm'). These are two stages starting with non-selective monoamineoxidase inhibitors (MAOI) or dopamine D2 receptor agonists (D2RAG) in 'monotherapy' (DATA1) and proposing to combine them in the event of a partial response (DATA2). The effectiveness of this approach in the management of TRAD has not yet been evaluated in routine care. The aim of this study is to evaluate the feasibility and effectiveness in routine care of the DATA recommendations in the management of TRAD presenting to a specialized consultation for resistant depression (short and long-term results).

Recruitment information / eligibility
Status Recruiting
Enrollment 60
Est. completion date March 22, 2024
Est. primary completion date March 2024
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Major patient (=18 years old) - Man or woman - Patient covered for consultation at the Expert Resistant Depression Center of Alsace (CEDRA) (CHU-Strasbourg branch) for TRAD between 01 January 2013 and 31 March 2023 - Patient not opposing to the reuse of their data for the purposes of this research Exclusion Criteria: - Patient having expressed opposition to participating in the study - Patient under judicial protection - Patient under guardianship or curatorship

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
France CENTRE DE NEUROMODULATION NON INVASIVE DE STRASBOURG (CEMNIS) - CHU de Strasbourg - France Strasbourg

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Proportion of patients in remission; Remission time; Survival curves for remissions and responses 3 months after the patient was taken care of at the Strasbourg University Hospital
See also
  Status Clinical Trial Phase
Recruiting NCT03851380 - Improving Brain Stimulation Through Imaging
Completed NCT04977674 - Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine Early Phase 1
Completed NCT03207282 - Treatment Resistant Depression in America Latina
Completed NCT02691520 - Epidemiology of Treatment Resistant Depression in Taiwan Phase 4
Completed NCT02452892 - Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) N/A
Active, not recruiting NCT04159012 - NESBID: Neuro-Stimulation of the Brain in Depression N/A
Recruiting NCT05870501 - Synaptic Imaging and Network Activity in Treatment Resistant Depression N/A
Completed NCT04239651 - rTMS With and Without iCBT For the Treatment of Resistant Depression (TRD) N/A
Completed NCT02493868 - A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression Phase 3
Completed NCT04599855 - A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression Phase 4
Completed NCT03283670 - Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies Phase 2
Recruiting NCT03004521 - Lithium Versus Quetiapine in Treatment Resistant Depression Phase 4
Recruiting NCT04783103 - Neuromodulation in the Elderly Depressed: a Brain Imaging Pilot Study N/A
Completed NCT03434041 - A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression Phase 3
Terminated NCT03887624 - Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression. Early Phase 1
Completed NCT02577250 - Ketamine Infusions for PTSD and Treatment-Resistant Depression Phase 1
Recruiting NCT02610712 - Clinical Trial of the Use of Ketamine in Treatment Resistant Depression Phase 4
Completed NCT03051256 - Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD Phase 2
Enrolling by invitation NCT05581797 - Psilocybin-assisted Interpersonal Therapy for Depression N/A
Completed NCT02782104 - A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression Phase 3